Abstract:We identified Runx2 as a HSC‐specific protein during liver fibrosis, which is essential for the regulation of HSC activation. Targeted knockout of Runx2 expression in HSC or intrahepatic overexpression of Runx2 significantly inhibited or promoted liver fibrosis induced by various factors. Importantly, we demonstrated that PKA/Runx2/Itgav signaling is a probable mechanism for regulating HSC activation in liver fibrosis, and pharmacological blockade of Itgav attenuated Runx2‐induced HSC activation and liver fibrosis, which suggests a critical and yet unappreciated role of Runx2 in the development and progression of liver fibrosis, and may provide a potential new therapeutic target for liver fibrosis. Backgrounds and aims As a central event during liver fibrosis, hepatic stellate cells (HSC) have been thought to be a potential therapeutic target for liver fibrosis. Previous studies have shown that runt‐related transcription factor 2 (Runx2) is associated with the development of non‐alcoholic fatty liver disease, while its specific role in HSC activation and hepatic fibrosis remains elusive. Approach and results In this study, we found that Runx2 expression was significantly upregulated in human liver fibrosis with different aetiologies. Runx2 expression was also gradually elevated in mouse liver during fibrosis, and Runx2 was mainly expressed in the activated HSC. Knockdown of Runx2 in HSC markedly alleviated CCl4‐induced, 3,5‐diethoxycarbonyl‐1,4‐dihydrocollidine‐induced or methionine‐choline deficient (MCD)‐induced liver fibrosis, while hepatic overexpression of Runx2 via HBAAV‐Runx2 or VA‐Lip‐Runx2 injection exacerbated CCl4‐induced liver fibrosis. In vitro analysis demonstrated that Runx2 promoted HSC activation and proliferation, whereas Runx2 knockdown in HSC suppressed these effects. RNA‐seq and Runx2 ChIP‐seq analysis demonstrated that Runx2 could promote integrin alpha‐V (Itgav) expression by binding to its promoter. Blockade of Itgav attenuated Runx2‐induced HSC activation and liver fibrosis. Additionally, we found that cytokines (TGF‐β1, PDGF, EGF) promote the expression and nuclear translocation of Runx2 through protein kinase A (PKA) in HSC. Conclusions Runx2 is critical for HSC activation via transcriptionally regulating Itgav expression during liver fibrosis, and may be a promising therapeutic target for liver fibrosis.

Runx2 activates hepatic stellate cells to promote liver fibrosis via transcriptionally regulating Itgav expression

PLK1 regulates hepatic stellate cell activation and liver fibrosis through Wnt/-catenin signalling pathway

ATF3‐mediated transactivation of CXCL14 in HSCs during liver fibrosis

Targeting Transforming Growth Factor Βrii Expression Inhibits the Activation of Hepatic Stellate Cells and Reduces Collagen Synthesis

The Upregulation of Leucine-Rich Repeat Containing 1 Expression Activates Hepatic Stellate Cells and Promotes Liver Fibrosis by Stabilizing Phosphorylated Smad2/3

MicroRNA-146b Regulates Hepatic Stellate Cell Activation Via Targeting of KLF4.

Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis

Ablation of serum response factor in hepatic stellate cells attenuates liver fibrosis

Ruxolitinib Suppresses Liver Fibrosis Progression and Accelerates Fibrosis Reversal Via Selectively Targeting Janus Kinase 1/2

Hypoxia-inducible factor 1/IL-6 axis in activated hepatic stellate cells aggravates liver fibrosis

Selective depletion of hepatic stellate cells-specific LOXL1 alleviates liver fibrosis

XIAP-mediated degradation of IFT88 disrupts HSC cilia to stimulate HSC activation and liver fibrosis

The IGF2BP3/Notch/Jag1 pathway: A key regulator of hepatic stellate cell ferroptosis in liver fibrosis

CXCL6-EGFR-induced Kupffer Cells Secrete TGF-beta 1 Promoting Hepatic Stellate Cell Activation Via the SMAD2/BRD4/C-MYC/EZH2 Pathway in Liver Fibrosis

Runt-related transcription factor-1 ameliorates bile acid–induced hepatic inflammation in cholestasis through JAK/STAT3 signaling

Igf2bp2 Knockdown Improves CCl4-induced Liver Fibrosis and TGF-β-activated Mouse Hepatic Stellate Cells by Regulating Tgfbr1

Endothelial RUNX3 controls LSEC dysfunction and angiocrine LRG1 signaling to prevent liver fibrosis

TET1 inhibits liver fibrosis by blocking hepatic stellate cell activation

Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis

Regulatory T cells (Tregs) in liver fibrosis

The HLF/IL-6/STAT3 Feedforward Circuit Drives Hepatic Stellate Cell Activation to Promote Liver Fibrosis